Neoplasm coding is one of the most complex areas of ICD-10-CM classification. Accurate coding requires understanding the Neoplasm Table, distinguishing primary from secondary malignancies, applying laterality rules, and properly sequencing treatment encounter codes. This guide covers the essential ICD-10 coding guidelines for Chapter 2 neoplasms (C00-D49).
Using the ICD-10-CM Neoplasm Table
The Neoplasm Table in the ICD-10-CM Alphabetic Index organizes neoplasm codes by anatomic site and behavior. Each row represents a body site, with six columns representing the behavior classification:
| Column | Behavior | Code Range |
|---|---|---|
| Malignant Primary | Original site of cancer | C00-C75, C7A, C76 |
| Malignant Secondary | Metastatic site | C77-C79 |
| Ca in situ | Non-invasive, localized | D00-D09 |
| Benign | Non-cancerous growth | D10-D36 |
| Uncertain Behavior | Pathology uncertain if malignant | D37-D48 |
| Unspecified Behavior | No pathology confirmation | D49 |
Critical Step
Always verify codes found in the Neoplasm Table against the Tabular List. The Tabular List may contain additional instructional notes (Excludes1, Code first, Use additional code) that affect code assignment.
Primary vs. Secondary Malignancies
Distinguishing primary from secondary (metastatic) sites is fundamental to accurate neoplasm coding. The primary site is where the cancer originated; secondary sites are where it has spread.
Coding Rules for Primary Malignancies
- Code the primary site using C00-C76 or C7A codes
- Specify laterality when applicable (e.g., right lung C34.91 vs. left lung C34.92)
- Specify the sub-site when documented (e.g., upper lobe C34.10 vs. lower lobe C34.30)
- Use unspecified codes like C34.90 only when documentation lacks laterality and sub-site
Coding Rules for Secondary Malignancies
- Code each metastatic site using C77-C79 codes
- Code both the primary and all documented secondary sites
- If the primary site is unknown, use C80.1 (Malignant neoplasm, unspecified site)
- If the primary site has been eradicated and only secondaries remain, use Z85.- for history of the primary with active secondary site codes
Sequencing: Which Comes First?
When a patient has both primary and secondary malignancies:
- Treatment directed at primary: Primary is the principal diagnosis
- Treatment directed at secondary: Secondary is the principal diagnosis
- Admission for both: Either may be principal, per provider documentation of the reason for encounter
Laterality and Site Specificity
ICD-10-CM requires laterality (right, left, bilateral) for paired organs. Failing to specify laterality when documented results in assignment of an unspecified code, which may trigger audits and denials.
- Lung: Right (C34.91) vs. Left (C34.92) vs. Unspecified (C34.90)
- Breast: Right (C50.911) vs. Left (C50.912) vs. Unspecified (C50.919)
- Kidney: Right (C64.1) vs. Left (C64.2) vs. Unspecified (C64.9)
Audit Risk
Unspecified laterality codes (e.g., C34.90) are flagged in RADV audits. Always review imaging and pathology reports for laterality before assigning an unspecified code. Query the provider if laterality is documented elsewhere in the record.
Gender-Specific Neoplasms
Certain neoplasm codes are gender-specific and will be rejected if assigned to the wrong gender:
- Male only: C61 (Malignant neoplasm of prostate), C62.- (Testicular cancer)
- Female only: C53.- (Cervical cancer), C54.- (Uterine cancer), C56.- (Ovarian cancer)
The ICD Code Auditor automatically validates gender-specific codes to prevent claim rejections.
Validate Neoplasm Codes Against ICD-10-CM Guidelines
Check neoplasm codes for gender conflicts, fiscal year validity, and sequencing compliance.
Look up ICD 10 CM codes to find the correct neoplasm code before validation.
Treatment Encounter Coding
When a patient presents specifically for cancer treatment (chemotherapy, radiation, immunotherapy), the sequencing depends on the reason for encounter:
Encounter Solely for Treatment
- Z51.11 – Encounter for antineoplastic chemotherapy (sequence first)
- Z51.0 – Encounter for antineoplastic radiation therapy (sequence first)
- Z51.12 – Encounter for antineoplastic immunotherapy (sequence first)
- Follow with the neoplasm code(s) as additional diagnoses
Encounter for Condition Plus Treatment
When the encounter addresses both the malignancy and administers treatment, sequence the neoplasm code as principal diagnosis, followed by the Z51.- code.
History vs. Active Neoplasm
After treatment has been completed and no evidence of disease remains:
- Use Z85.- (Personal history of malignant neoplasm) for the primary site
- Do NOT assign Z85.- while the neoplasm is still under active treatment
- If the neoplasm recurs, assign the appropriate C-code, not Z85.-
- Continue to code secondary sites that are still under treatment with C77-C79
Commonly Coded Neoplasms
The following neoplasm codes are among the most frequently assigned in clinical practice:
- C34.90 – Malignant neoplasm of unspecified part of bronchus or lung
- C61 – Malignant neoplasm of prostate
- C50.919 – Malignant neoplasm of unspecified site of unspecified female breast
- C18.9 – Malignant neoplasm of colon, unspecified
View all commonly used ICD-10 codes in our ICD-10 Code Directory.
Documentation Tips for Neoplasm Coding
- Always document the anatomic site, laterality, and histologic type
- Specify current treatment status (active treatment, surveillance, history)
- Document all metastatic sites identified on imaging or pathology
- Record whether the primary has been excised, is still present, or is unknown
- Note complications of treatment (e.g., anemia due to chemotherapy)
For a deeper dive into documentation practices, see our Cancer Coding Documentation Guide. Learn about MEAT documentation for risk adjustment of neoplasm codes that map to HCC categories.